Semaglutide pill for liver fat in transplant patients with diabetes
Part of Hormones & metabolism clinical trials.
This study tests if an oral semaglutide pill can reduce liver fat and improve body composition in people who have had a liver transplant and have diabetes. It may help manage weight and blood sugar after transplant.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are 30 years or older
- Your liver transplant was at least 3 months ago
- You have diabetes and take metformin and/or insulin, with HbA1c (average blood sugar) of 9% or less
- Your body mass index (BMI) is above 25 (overweight or obese)
- You are medically stable and agree to follow study rules
- You are willing to have an MRI (magnetic resonance imaging) scan
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether an oral medication called semaglutide can help people with type 2 diabetes, fatty liver, and kidney problems. It aims to see if it can improve kidney function and liver health.
This trial tests semaglutide (a diabetes/weight-loss medicine) to help prevent weight gain after liver transplant. It is also looking at blood sugar and safety while you continue your transplant medicines.
This trial tests whether the medication semaglutide (often used for diabetes) can prevent the development of new diabetes after a kidney transplant. If you are in the early weeks after a transplant and have risk factors for diabetes, this study might help reduce your chances of developing diabetes later.
This trial tests semaglutide, a medicine that helps lower blood sugar, in people who develop high blood sugar shortly after a kidney transplant. It may help control blood sugar without harming the transplanted kidney, while also checking safety in this specific group.
This Phase 2 study tests how semaglutide (a diabetes medication also used for weight) affects fatty liver and the liver’s response to sugar. It may help people with non-alcoholic fatty liver disease understand whether the drug improves liver fat and related changes.
This study tests whether semaglutide, a medicine that helps control blood sugar and reduce weight, can benefit adults with type 1 diabetes who are overweight. If you qualify, you may receive the drug or a placebo, and the study team will monitor your health closely.
Hear when a new Liver Transplant; Complications trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.